Product Information
PHENDIMETRAZINE ER 105 MG CAP is a generic product labeled by Acertis Pharmaceuticals, LLC, priced at $3.3821 per EA under NDC 72989040930. Its NADAC has been published 182 times since Apr 12, 2023.
FDA first approved this application before 1982.
The High Outlier badge above means this manufacturer's average price in the PHENDIMETRAZINE TARTRATE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
105 mg/1
Manufacturer
Acertis Pharmaceuticals, LLCNDC
72989040930
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PHENDIMETRAZINE TARTRATEApproval Type
New Drug (NDA)
FDA Application
NDA018074FDA Approved
Before 1982
On Market Since
11/1/2022
Pharmacological Classes
Price Statistics
The NADAC for PHENDIMETRAZINE ER 105 MG CAP has been published 182 times since Apr 12, 2023, and over the history we have for it it has risen 35.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.3821 per EA |
|---|---|
| All-time high | $3.3821 (Sep 30, 2026) |
| All-time low | $2.4773 (May 17, 2023) |
| 52-week high | $3.3821 |
| 52-week low | $3.0759 |
| Median price | $2.8567 |
| Average price | $2.8511 |
| Largest weekly change | +15.1% (Apr 17, 2024) |
| Weeks tracked | 182 |
| Tracking since | Apr 12, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PHENDIMETRAZINE TARTRATE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Acertis Pharmaceuticals, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PHENDIMETRAZINE TARTRATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Sympathomimetic Amine Anorectic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PHENDIMETRAZINE ER 105 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for PHENDIMETRAZINE ER 105 MG CAP, manufactured by Acertis Pharmaceuticals, LLC, is $3.3821 per EA (NDC 72989040930), effective Sep 30, 2026.
How has the price of PHENDIMETRAZINE ER 105 MG CAP changed over time?
Over the history we have for it, the NADAC for PHENDIMETRAZINE ER 105 MG CAP has risen 35.6%. It has been tracked across 182 weekly CMS publications since Apr 12, 2023.
What are the highest and lowest recorded NADAC prices for PHENDIMETRAZINE ER 105 MG CAP?
Since Apr 12, 2023, the NADAC for PHENDIMETRAZINE ER 105 MG CAP has ranged from a low of $2.4773 (May 17, 2023) to a high of $3.3821 (Sep 30, 2026), with a median of $2.8567 per EA.
Are there cheaper alternatives to PHENDIMETRAZINE ER 105 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of PHENDIMETRAZINE ER 105 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PHENDIMETRAZINE ER 105 MG CAP?
PHENDIMETRAZINE ER 105 MG CAP (NDC 72989040930) is labeled by Acertis Pharmaceuticals, LLC, and CMS classifies it as a generic product.